TruSight™ Oncology 500 v2 (TSO 500 v2) is an updated next-generation sequencing (NGS) assay designed to enable laboratories with in-house comprehensive genomic profiling (CGP) from formalin-fixed, paraffin-embedded (FFPE) tissue samples. Building on the success of its predecessor, TSO 500 v2 targets 523 genes and assesses a wide range of biomarkers—including SNVs, CNVs, indels, fusions, Tumor Mutational Burden (TMB), Microsatellite Instability (MSI), and Homologous Recombination Deficiency (HRD)—with enhanced sensitivity, coverage, scalability, scalability, and bioinformatics workflows.

This webinar will unveil the latest advancements in TSO 500 v2, showcasing its applications through oncology research insights. Join us to hear from experts at Illumina and Instituto Catalan de Oncologia (Spain) early performance data including, Illumina developed results and early access findings from DNA, RNA, and HRD analysis.

Attendees will gain a practical understanding of the assay’s usability in the lab, its improvements over TSO 500 v1, and its relevance to clinical research and precision oncology. The session will conclude with a live Q&A to address your questions on product features and research implications.

Learning Objectives:

Discuss CGP capabilities for DNA and RNA from FFPE samples highlighting improvements over previous versions and relevance to clinical research and precision oncology
Showcase TSO 500 v2 performance in DNA analysis
Review a laboratory experience and kit usability of TSO 500 v2 RNA and HRD analysis capabilities using ICO data

Product Information

Heather Robinson

Oncology Product Manager, Illumina

Appearances